The influence of moderate red wine consumption on antioxidant status and indices of oxidative stress associated with CHD in healthy volunteers

Catherine Tsang1, Siobhan Higgins2, Garry G. Duthie3, Susan J. Duthie3, Moira Howie4†, William Mullen1, Michael E. J. Lean5 and Alan Crozier1*

1Plant Products and Human Nutrition Group, Division of Biochemistry and Molecular Biology, University of Glasgow, Glasgow G12 8QQ, UK
2Department of Human Nutrition, University of Glasgow, Yorkhill Hospitals, Glasgow G3 8SJ, UK
3Rowett Research Institute, Greenburn Road, Bucksburn, Aberdeen AB21 9SB, UK
4Safeway Stores plc, 6 Millington Road, Hayes, Middlesex, UB3 4AY, UK
5Department of Human Nutrition, University of Glasgow, Queen Elizabeth Building, Royal Infirmary, Glasgow G23 2ER, UK

(Received 20 April 2004 – Revised 24 September 2004 – Accepted 26 September 2004)

The effects of moderate red wine consumption on the antioxidant status and indices of lipid peroxidation and oxidative stress associated with CHD were investigated. A randomised, controlled study was performed with twenty free-living healthy volunteers. Subjects in the red wine group consumed 375 ml red wine daily for 2 weeks. We measured the total concentration of phenolics and analysed the individual phenolics in the wine and plasma by HPLC with tandem MS. The antioxidant capacity of plasma was measured with electron spin resonance spectroscopy while homocysteine and fasting plasma lipids were also determined. The production of conjugated dienes and thiobarbituric acid-reactive substances (TBARS) were measured in Cu-oxidised LDL. Plasma total phenolic concentrations increased significantly after 2 weeks of daily red wine consumption (P≤0.001) and trace levels of metabolites, mainly glucuronides and methyl glucuronides of (+)-catechin and (−)-epicatechin, were detected in the plasma of the red wine group. These flavan-3-ol metabolites were not detected in plasma from the control group. The maximum concentrations of conjugated dienes and TBARS in Cu-oxidised LDL were reduced (P≤0.05) and HDL cholesterol concentrations increased (P≤0.05) following red wine consumption. The findings from the present study provide some evidence for potential protective effects of moderate consumption of red wine in healthy volunteers.

Red wine: Phenolics: Conjugated dienes: Thiobarbituric acid-reactive substances

There is much public, media and scientific interest in the possibility that red wine may be protective against CHD. Mounting evidence suggests that moderate red wine consumption is inversely associated with CHD, an association popularised as the ‘French paradox’ (Renaud & De Logeril, 1993). The paradox describes the seemingly low mortality rates among certain populations in France despite high levels of associated risk factors: serum cholesterol, systolic blood pressure, dietary fat intakes and low consumption of fruits and vegetables. It is speculated that this paradox is associated with the widespread consumption of red wine (Criqui & Ringel, 1994). Although there is evidence to suggest that a light to moderate intake of alcohol is beneficial to health (Albert et al. 1999), it has been shown that red wine provides additional health benefits beyond those of alcohol alone (Rimm et al. 1996; Burns et al. 2001a).

The putative cardio-protective effects of red wine have largely been attributed to the abundance of phenolic compounds. Plant-derived phenolics are widely distributed in nature and are present in varying amounts in commonly consumed fruits, vegetables and beverages (Duthie & Crozier, 2003; Saltmarsh et al. 2003). Red wine provides an especially rich source of these compounds, which originate from grape seeds, skins and wine stems (Singleton, 1982). The levels of phenolic acids, major catechins and anthocyanins in red wine vary depending on the grape variety and vintage (Landrault et al. 2001), as well as on climate and vinification practices (Goldberg et al. 1998; Burns et al. 2001b). Generally, red wines contain between 1000 and 4000 mg phenolics/l, the majority of which are derived from anthocyanins and proanthocyanidins (Burns et al. 2000).

Although the exact mechanisms of the protection conferred by red wine are unknown, there is evidence that phenolic compounds act as antioxidants by protecting the body from damaging oxidation reactions caused by free radicals (Kanner et al. 1994). There is further evidence that they...
may inhibit oxidative modification of LDL based on their ability to increase the resistance of isolated LDL to Cu oxidation in vitro (Frankel et al. 1995). Several studies have demonstrated that many dietary phenolics protect against the oxidative modification of LDL in vitro (Vinson & Hontz, 1995; Teissedre et al. 1996). Despite increasing evidence for the in vitro effectiveness of phenolics, there remains a dearth of information regarding their efficacy in vivo and this may be due, in part, to a lack of knowledge on their bioavailability in man. The results from wine trials to date have presented conflicting results, with some showing a protective effect following red wine intake (Serafini et al. 1998; Natella et al. 2001) while others have not demonstrated such an effect (van Golde et al. 1999).

The present paper reports the results of an intervention study in which the influence of red wine consumption on the antioxidant status and on indices of oxidative stress associated with CHD was investigated in healthy volunteers.

**Methods**

**Study design**

A randomised, controlled study was performed with twenty free-living healthy volunteers. Subjects were non-smokers, aged between 23 and 50 years, who were not taking medications or vitamin supplements. The study protocol was approved by the Research Ethics Committee, Glasgow Royal Infirmary, UK. Written informed consent was obtained from each volunteer. Subjects were randomised into two groups: red wine; control. Volunteers were required to avoid all alcohol and foods/beverages rich in polyphenols, and to limit fruit and vegetable intake over the study period. Subjects in the red wine group were asked to consume 375 ml red wine (1999 Bulgarian Young Vatted Cabernet Sauvignon, 12 % alcohol Safeway, Hayes, UK) each day for 2 weeks. Fasting blood samples obtained at weekly intervals were collected into EDTA and lithium heparin tubes. Plasma was immediately separated by low-speed centrifugation (2500 g for 10 min at 4°C) and stored at −80°C prior to analysis. For vitamin C analysis, 0·6 ml plasma was mixed with an equal volume of 10 % (w/v) meta-phosphoric acid, snap-frozen in liquid N and stored at −80°C prior to analysis. Subjects were required to record food and beverage intake over the study period and this information was used to assess compliance with the dietary instructions given.

**Measurement of plasma carotenoids, tocopherols and retinol**

The levels of six carotenoids (lutein/zeaxanthin, β-cryptoxanthin, lycopene, α-carotene and β-carotene), retinol and α- and γ-tocopherol in plasma were measured by reversed-phase HPLC with absorbance and fluorimetric detection according to the method of Hess et al. (1991). The analysis was conducted under the auspices of the US National Institute of Standards Quality Assurance Scheme for fat-soluble vitamins; full details of the method are given in Duthie (1999).

**Determination of ascorbic acid**

Ascorbic acid content was determined from 0·6 ml plasma and measured by ion-pair reversed-phase HPLC with UV detection (Ross, 1994). Analysis was conducted under the US National Institute of Standards Quality Assurance Scheme for vitamin C analysis in biological fluids and the method is described in detail in Duthie (1999).

**Plasma antioxidant capacity**

Antioxidant capacity of plasma was measured using electron spin resonance spectroscopy as described by Gardner et al. (1998). This assay is based on the ability of antioxidants in plasma to donate a hydrogen atom or electron to the synthetic free radical, potassium nitrodisulphonate (Fremy’s salt).

**Total phenolic concentrations**

Total phenolics were measured in red wine using the Folin–Ciocalteau method (Singleton & Rossi, 1965) with data expressed as gallic acid equivalents. Total phenols in plasma were also estimated with Folin–Ciocalteau reagent using a modification of the method of Swaine & Hillis (1959), which avoids interference from proteins in biological samples (Serafini et al. 1998).

**Determination of conjugated dienes and thiobarbituric acid-reactive substances**

LDL was isolated from plasma by density-gradient ultracentrifugation at 35 000 rpm for 15 h at 15°C. The LDL fraction was removed and samples were dialysed at 4°C against 40 litres PBS containing 10 μM-Na2EDTA (pH 7·4) for 42 h while shaking gently in a microdialysis unit (GibcoBRL, Life Technologies Ltd, Paisley, UK). The protein concentration of dialysed LDL was analysed according to the method of Markwell et al. (1981). Samples were adjusted to a concentration of 50 μg LDL protein/ml and 1 μM-EDTA in quartz cuvettes. Oxidation of LDL was initiated by addition of 15 μM-CuSO4 (Kleinveld et al. 1992). Absorbance of the samples was measured at 234 nm, every 2 min at 30°C. Maximal oxidation rate (nmol/mg LDL protein per min), maximal diene concentration (nmol/mg LDL protein) and lag phase (min) were estimated using exact coordinates provided by the kinetics software application (Beckman Instruments Inc., Fullerton, CA, USA).

LDL that was oxidised for measurement of conjugated dienes was subsequently used for the measurement of thiobarbituric acid-reactive substances (TBARS; Buege & Aust, 1978). Following oxidation for 3 h, the reaction was stopped by addition of 200 μM-EDTA and 40 μM-butylated hydroxytoluene and the samples stored at 4°C for a maximum of 7 d. TBARS were determined by adding 1·6 ml TCA–TBA–HCl reagent (15 % trichloroacetic acid–0·375 % thiobarbituric acid–0·25 mol HCl) to a 0·8 ml aliquot of the LDL solution (oxidised as above), mixing the sample and then heating it in boiling water at 100°C for 15 min. After placing the tubes in a bath of cold water for 5 min, samples were centrifuged for 10 min at 2000 rpm. Absorbance was measured at 535 nm.
and quantification of TBARS was performed by comparison with a standard curve of malonaldehyde equivalents generated by acid-catalysed hydrolysis of 1,1,3,3-tetraethoxypropane (Sigma Chemical Co., Poole, Dorset, UK).

**Homocysteine concentrations**

Plasma homocysteine (200 µl) was measured using a DS30 Hcy homocysteine assay kit and a DS30 analyser (Drew Scientific Ltd, Barrow-in-Furness, Cumbria, UK) according to the method of Duthie et al. (2002). Quantitative evaluation of the homocysteine concentration was achieved by comparison with a two-point calibration.

**Fasting plasma lipids**

Fasting plasma lipids including total cholesterol, HDL cholesterol, LDL cholesterol and triacylglycerol concentrations were determined using an automated Hitachi 197 multichannel analyser (Roche Diagnostics, Lewes, East Sussex, UK) using standard procedures. LDL cholesterol concentrations were calculated using the Friedewald formula (Friedewald et al. 1972).

**Extraction and measurement of phenolics in plasma**

Plasma was extracted according to a modified method of Day et al. (2001). Briefly, 1·5 ml acetonitrile was added to 0·5 ml stabilised plasma. Samples were vortexed for 30 s every 2 min over a 10 min period, before centrifugation at 4000 g for 20 min. The supernatant was removed and the pellet was further extracted with 1·5 ml methanol, then the process was repeated again as described. The two supernatants were mixed and dried in a centrifugal vacuum concentrator at 38 °C. Four hundred and fifty µl 1 % formic acid in 50 µl methanol was added to the dried pellet, centrifuged at 25 000 g for 10 min and analysed by HPLC with tandem MS.

**HPLC with tandem MS**

Wine and plasma (100 µl), extracted as earlier, at baseline and after 2 weeks in the red wine and control group, was injected and analysed on a Surveyor HPLC system comprising an HPLC pump, a diode array detector scanning from 250 to 700 nm and an auto sampler set at 4 °C (Thermo Finnigan, San Jose, CA, USA). Separation was carried out using a 250 mm x 4·6 mm (inner diameter) 4 µm Synergi RP-Max column (Phenomenex, Macclesfield, Cheshire, UK) eluted at a flow rate of 1 ml/min. A 5–40 % gradient over 60 min of 0·1 % formic acid and acetonitrile was used for the complete separation of all compounds. After passing through the flow cell of the diode array detector, the column eluate was split and 0·3 ml was directed to an LCQ Deca XP ion-trap mass spectrometer fitted with an electrospray interface (Thermo Finnigan). Analysis was carried out in full-scan mode from 100 to 2000 amu using the positive-ion mode when analysing anthocyanins and with negative ionisation for all other compounds. Selective reaction monitoring was additionally used to detect selected ions in the plasma.

**Statistical analysis**

Mean values and standard errors were calculated for all measurements. Analysis of the significance of the differences observed between measurements within the same group before and after the intervention was done by the paired t test. A two-sample t test for independent analysis of samples was used to compare between the values obtained from the intervention and control groups at baseline and following 2 weeks of red wine consumption. Data were analysed using the Minitab statistical software package, version 4·0. (Minitab Inc., Addison-Wesley Publishing Co., Reading, MA, USA). The differences were considered statistically significant at _P_ ≤ 0·05.

**Results**

Subjects were all healthy non-smokers. No statistically significant differences were observed in mean age (35 (se 2·5) and 29 (se 2·5) years), height (1·67 (se 0·1) and 1·65 (se 0·1) m), weight (68·3 (se 1·9) and 67 (se 3·2) kg) or BMI (22·5 (se 0·3) and 23·2 (se 1·2) kg/m²) between the groups. Consumption of red wine was associated with a small but significant increase (_P_ ≤ 0·05, unpaired _t_ test) in total phenolic concentration in plasma. This was reflected by a 7 % increase in plasma antioxidant capacity that failed to achieve statistical significance (Table 2). No change in plasma total phenolic concentration or antioxidant capacity was observed in the control group. There were no significant changes in the plasma concentrations of α- and γ-tocopherol, retinol and ascorbic acid. Similarly, no differences were observed between the groups in plasma concentrations of the individual carotenoids and data are therefore presented as total carotenoids in Table 2.

The maximum concentration of conjugated dienes produced in Cu-oxidised LDL was reduced significantly (_P_ = 0·026, paired _t_ test; Table 3) in the red wine group after 2 weeks, as was the TBARS concentration in Cu-oxidised LDL (_P_ = 0·050, paired _t_ test; Table 3). There were no significant changes observed in conjugated dienes or TBARS in the control group. There was a significant increase (_P_ = 0·02, paired _t_ test) in the concentration of HDL cholesterol after 2 weeks in the red wine group while no change was observed in the control group. No significant change was observed in other fasting lipids or in homocysteine in either group (Table 3).

HPLC with tandem MS in the selective reaction monitoring mode detected trace amounts of flavan-3-ol glucuronides in the plasma of subjects from the red wine group and are summarised in Table 1. Statistical analysis of the concentrations of the individual carotenoids and data are therefore presented as total carotenoids in Table 2.
corresponding to (+)-catechin/(-)-epicatechin at m/z 289 and 245. The [M – H]– – 176 loss is in keeping with the cleavage of a glucuronyl unit. The MS fragmentation pattern, together with the HPLC elution order, indicates that the earlier-eluting M-1 peak is a (+)-catechin glucuronide while M-2 is an (–)-epicatechin glucuronide. Peaks M-3 (tR = 21.6 min, λmax = 280 nm) and M-4 (tR = 27.1 min, λmax = 280 nm) also had similar mass spectra, with [M – 2H]2 at m/z 479 which on loss of 176 amu (loss of a glucuronyl unit) yielded an MS2 ion at m/z 303. These fragments are 14 amu higher than the equivalent ions in the spectra of M-1 and M-2, indicating

Table 1. Identification of flavonoids and phenolic compounds in Young Vatted Bulgarian Cabernet Sauvignon red wine based on HPLC retention times (tR), absorbance maximum (λmax) and tandem MS data obtained in full-scan negative- and positive-ion modes*

(Amount ingested daily is mean value and standard error for three determinations)

<table>
<thead>
<tr>
<th>Peak</th>
<th>tR (min)</th>
<th>λmax (nm)</th>
<th>Compound</th>
<th>[M – H]– (m/z)</th>
<th>MS2 ions (m/z)</th>
<th>Mean (mg/375 ml)</th>
<th>SE</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5.3</td>
<td>265</td>
<td>Gallic acid</td>
<td>169</td>
<td>125</td>
<td>59.6 (mg/375 ml)</td>
<td>2.0</td>
</tr>
<tr>
<td>2</td>
<td>6.9</td>
<td>280</td>
<td>Procyanidin trimer C2</td>
<td>865</td>
<td>577</td>
<td>3.2 (mg/375 ml)</td>
<td>0.2</td>
</tr>
<tr>
<td>3</td>
<td>13.4</td>
<td>280</td>
<td>Procyanidin dimer B1</td>
<td>577</td>
<td>425, 407</td>
<td>14.7 (mg/375 ml)</td>
<td>0.4</td>
</tr>
<tr>
<td>4</td>
<td>14.3</td>
<td>515</td>
<td>Delphinidin-3-glucoside</td>
<td>465†</td>
<td>303 [Del], ([M + H]+ – Glc)</td>
<td>2.7 (mg/375 ml)</td>
<td>0.1</td>
</tr>
<tr>
<td>5</td>
<td>15.3</td>
<td>280</td>
<td>(+)-Catechin</td>
<td>289</td>
<td>163, 125</td>
<td>16.1 (mg/375 ml)</td>
<td>0.2</td>
</tr>
<tr>
<td>6</td>
<td>17.8</td>
<td>515</td>
<td>Petunidin-3-glucoside</td>
<td>479†</td>
<td>317 [Pet], ([M + H]+ – Glc)</td>
<td>2.8 (mg/375 ml)</td>
<td>0.1</td>
</tr>
<tr>
<td>7</td>
<td>18.9</td>
<td>280</td>
<td>Procyanidin dimer B2</td>
<td>577</td>
<td>425, 407</td>
<td>16.8 (mg/375 ml)</td>
<td>0.1</td>
</tr>
<tr>
<td>8</td>
<td>19.8</td>
<td>280</td>
<td>(–)-Epicatechin</td>
<td>289</td>
<td>163, 125</td>
<td>15.9 (mg/375 ml)</td>
<td>1.0</td>
</tr>
<tr>
<td>9</td>
<td>20.0</td>
<td>510</td>
<td>Peonidin-3-glucoside</td>
<td>463†</td>
<td>301 [Peo], ([M + H]+ – Glc)</td>
<td>1.1 (mg/375 ml)</td>
<td>0.1</td>
</tr>
<tr>
<td>10</td>
<td>21.0</td>
<td>515</td>
<td>Malvidin-3-glucoside</td>
<td>493†</td>
<td>331 [Mal], ([M + H]+ – Glc)</td>
<td>16.0 (mg/375 ml)</td>
<td>1.6</td>
</tr>
<tr>
<td>11</td>
<td>21.8</td>
<td>280</td>
<td>Procyanidin trimer C1</td>
<td>865</td>
<td>577</td>
<td>5.4 (mg/375 ml)</td>
<td>1.7</td>
</tr>
<tr>
<td>12</td>
<td>25.0</td>
<td>510</td>
<td>Vitisin B</td>
<td>517†</td>
<td>355</td>
<td>2.4 (mg/375 ml)</td>
<td>0.1</td>
</tr>
<tr>
<td>13</td>
<td>25.0</td>
<td>370</td>
<td>Myricetin glucoside</td>
<td>479</td>
<td>317 [Myr], ([M – H]– – Glc)</td>
<td>0.4 (mg/375 ml)</td>
<td>0.0</td>
</tr>
<tr>
<td>14</td>
<td>29.1</td>
<td>515</td>
<td>Malvidin-3-acetylglucoside</td>
<td>535†</td>
<td>331 [Mal], ([M + H]+ – AGlc)</td>
<td>2.4 (mg/375 ml)</td>
<td>0.0</td>
</tr>
<tr>
<td>15</td>
<td>29.6</td>
<td>350</td>
<td>Quercetin-3-glucuronide</td>
<td>477</td>
<td>301 [Q], ([M – H]– – GlcUA)</td>
<td>0.7 (mg/375 ml)</td>
<td>0.0</td>
</tr>
<tr>
<td>16</td>
<td>34.4</td>
<td>350</td>
<td>Myricetin</td>
<td>317</td>
<td></td>
<td>1.4 (mg/375 ml)</td>
<td>0.0</td>
</tr>
<tr>
<td>17</td>
<td>35.2</td>
<td>525</td>
<td>Malvidin-3-(p-coumaroyl) glucoside</td>
<td>633†</td>
<td>331 [Mal], ([M + H]+ – PGLc)</td>
<td>1.0 (mg/375 ml)</td>
<td>0.1</td>
</tr>
<tr>
<td>18</td>
<td>43.5</td>
<td>370</td>
<td>Quercetin</td>
<td>301</td>
<td></td>
<td>2.2 (mg/375 ml)</td>
<td>0.0</td>
</tr>
<tr>
<td>19</td>
<td>51.0</td>
<td>370</td>
<td>Kaempferol</td>
<td>285</td>
<td></td>
<td>0.1 (mg/375 ml)</td>
<td>0.0</td>
</tr>
</tbody>
</table>

[M – H]–, negatively charged molecular ion; MS2, secondary MS; Del, delphinidin; [M + H]+, positively charged molecular ion; Glc, glucosyl; Pet, petunidin; Peo, peonidin; Mal, malvidin; Myr, myricetin; AGlc, acetylglucosyl; Q, quercetin; GlcUA, glucuronyl; PGLc, p-coumaroylglucosyl.

*Peak numbers and tR values refer to peaks in Fig. 1.

†Positively charged molecular ion ([M + H]+).
the presence of methylated flavan-3-ol glucuronides. M-3 is therefore probably a methyl catechin glucuronide and the later-eluting M-4 a methyl epicatechin glucuronide (Table 4). Without reference compounds it was not possible to determine the positions on the flavan-3-ol skeleton of the methyl and glucuronic acid substituents. The most likely candidates for M-2 and M-4 are (–)-epicatechin-3'-O-glucuronide and 4'-O-methyl-(–)-epicatechin-3'-O-glucuronide, which have been identified as the main metabolites in human plasma after ingestion of (–)-epicatechin. Other methylated and glucuronide conjugates of (–)-epicatechin were, however, also present, albeit in smaller amounts (Natsume et al. 2003). None of the four flavan-3-ol metabolites was detected in the plasma of subjects from the control group.

### Discussion

There is a growing awareness of the potential health benefits of diets rich in fruits and vegetables and nutritional guidelines indicate that an increase in the consumption of foods rich in antioxidant nutrients may decrease the

**Table 2.** Antioxidant capacity, total phenolics, tocopherols, retinol, carotenoids and ascorbic acid content of plasma collected from human volunteers consuming 375 ml red wine daily for a 2-week period (n 12) and from a control group (n 8) (Mean values and their standard errors)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Red wine group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After 2 weeks</td>
</tr>
<tr>
<td>Antioxidant capacity (% Fremy’s radical reduced/l)</td>
<td>37·4 ± 2·5</td>
<td>40·5 ± 3·3</td>
</tr>
<tr>
<td>Total phenolics (μmol GAE/l)</td>
<td>12·4 ± 5·9</td>
<td>16·6* ± 5·9</td>
</tr>
<tr>
<td>α-Tocopherol (μmol/l)</td>
<td>25·3 ± 1·9</td>
<td>23·2 ± 0·9</td>
</tr>
<tr>
<td>γ-Tocopherol (μmol/l)</td>
<td>1·0 ± 0·2</td>
<td>1·2 ± 0·2</td>
</tr>
<tr>
<td>Retinol (μmol/l)</td>
<td>2·4 ± 0·0</td>
<td>2·1 ± 0·3</td>
</tr>
<tr>
<td>Total carotenoids (μmol/l)</td>
<td>1·8 ± 0·2</td>
<td>1·4 ± 0·2</td>
</tr>
<tr>
<td>Ascorbic acid (μmol/l)</td>
<td>63·5 ± 5·8</td>
<td>54·3 ± 7·4</td>
</tr>
</tbody>
</table>

GAE, gallic acid equivalents.
Statistically significant difference within each group based on paired t test: **P<0·001.
Statistically significant difference between intervention and control groups based on unpaired t test: †P<0·05.

**Table 3.** Maximum diene concentration, maximal oxidation rate and lag phase before rapid onset of conjugated diene production and thiobarbituric acid-reactive substances (TBARS) in copper-oxidised LDL, fasting plasma total, LDL and HDL cholesterol concentrations, fasting triacylglycerol (TAG) concentration and homocysteine level in plasma of human volunteers consuming 375 ml red wine daily for 2 weeks (n 12) and from a control group (n 8) (Mean values and their standard errors)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Red wine group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After 2 weeks</td>
</tr>
<tr>
<td>Maximum diene concentration (nmol/mg LDL protein)</td>
<td>913 ± 85</td>
<td>715* ± 53</td>
</tr>
<tr>
<td>Maximal oxidation rate (nmol/mg LDL protein per min)</td>
<td>9·4 ± 1·2</td>
<td>7·4 ± 0·6</td>
</tr>
<tr>
<td>Lag phase (min)</td>
<td>43·8 ± 3·7</td>
<td>49·8 ± 2·9</td>
</tr>
<tr>
<td>TBARS (nmol/mg LDL protein)</td>
<td>69·0 ± 8·3</td>
<td>50·6* ± 5·6</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>4·5 ± 0·3</td>
<td>4·9 ± 0·3</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/l)</td>
<td>2·7 ± 0·2</td>
<td>2·9 ± 0·2</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1·4 ± 0·1</td>
<td>1·5* ± 0·1</td>
</tr>
<tr>
<td>TAG (mmol/l)</td>
<td>0·8 ± 0·1</td>
<td>0·9 ± 0·1</td>
</tr>
<tr>
<td>Homocysteine (μmol/l)</td>
<td>8·1 ± 0·8</td>
<td>7·8 ± 0·7</td>
</tr>
</tbody>
</table>

Statistically significant difference within each group based on paired t test: *P<0·05.

**Table 4.** HPLC and mass spectral properties of metabolites detected in plasma of human volunteers after consuming 375 ml red wine daily for a 2-week period

<table>
<thead>
<tr>
<th>Peak</th>
<th>tR (min)</th>
<th>Metabolite</th>
<th>[M – H]⁻ (m/z)</th>
<th>MS² ions (m/z)</th>
</tr>
</thead>
<tbody>
<tr>
<td>M-1</td>
<td>16·6</td>
<td>(–)-Catechin glucuronide</td>
<td>465</td>
<td>289; 245 (C; [M – H]⁻ – GlcUA)</td>
</tr>
<tr>
<td>M-2</td>
<td>23·0</td>
<td>(–)-Epicatechin glucuronide</td>
<td>465</td>
<td>289; 245 (EC; [M – H]⁻ – GlcUA)</td>
</tr>
<tr>
<td>M-3</td>
<td>21·6</td>
<td>Methyl catechin glucuronide</td>
<td>479</td>
<td>303 (MC; [M – H]⁻ – GlcUA)</td>
</tr>
<tr>
<td>M-4</td>
<td>27·1</td>
<td>Methyl epicatechin glucuronide</td>
<td>479</td>
<td>303 (MEC; [M – H]⁻ – GlcUA)</td>
</tr>
</tbody>
</table>

tR, retention time; [M – H]⁻, negatively charged molecular ion; MS², secondary MS; C, (–)-catechin; GlcUA, glucuronyl unit; EC, (–)-epicatechin; MC, methyl catechin; MEC, methyl epicatechin.
risk of CHD and certain cancers (The Scottish Office, 1993). Epidemiological studies have reported a reduction in the incidence of CHD with moderate daily red wine consumption, an anomaly referred to as the ‘French paradox’. This effect has been ascribed to the low-molecular-weight phenolics in many plant-based foods, which can act as antioxidants because their extensive conjugated π-electron systems allow ready donation of electrons or hydrogen atoms from the hydroxyl moieties to free radicals (Scott, 1997).

In the present study, moderate daily consumption of red wine for 2 weeks resulted in a small but significant increase of 4-4 μmol gallic acid equivalents/l in plasma total phenolics, which was associated with a non-significant increase in antioxidant capacity (Table 2). This is in contrast with several studies that have measured increases in both total phenols and plasma antioxidant activity at various times up to 24 h following the consumption of red wine (Maxwell et al. 1994; Whitehead et al. 1995; Day et al. 1997; Duthie et al. 1998; Serafini et al. 1998). However, in such studies, the increases in plasma phenolics and antioxidant capacity begin to decline within 4 h of wine ingestion. In the present study, blood samples for the measurement of antioxidant capacity were taken in the morning, about 10–12 h after the consumption of red wine the previous evening, by which time the majority of the phenolics may have cleared from the blood. The data obtained indicate that regular red wine intake over 2 weeks does not lead to a sustained increase in total phenols in the circulation.

In the present study, there was a significant increase in the concentration of HDL cholesterol \((P=0.05)\) in the red wine group post-intervention (Table 3). However, the change is small and unlikely to be of clinical significance.

There were no significant differences (unpaired t tests) in the lag phase or any of the other indices of LDL oxidation between the red wine and control groups, post-intervention (Table 3). However, within the red wine group (paired t test), there was a significant reduction in the maximum concentration of conjugated dienes \((P=0.05)\) and TBARS \((P=0.05)\) post-intervention. While the lag phase was not increased significantly in the red wine group, there was an increase in eight of the twelve subjects. Our finding of a significant reduction in the concentration of conjugated dienes and TBARS without a statistically significant increase in the lag phase could lead one to suspect that there had been changes in LDL particle fatty acid composition. However, while we did not measure the LDL fatty acid composition, analysis using a computerised version of the food composition tables (Holland et al. 1991) of the subjects’ daily diet records for the period of the trial revealed no significant changes in either the quantity or the quality of dietary fat intake. It is very unlikely, therefore, that the fat composition of the LDL particle was altered for eight of the twelve subjects and the four who responded differently were distinct in this respect. Thus, while there was not a statistically significant reduction in susceptibility of LDL to oxidation compared with the control group, changes within the red wine group appear to show some protection against LDL oxidation. This is mostly likely to be due to the small but statistically significant increase in the plasma concentration of phenolics, which can bind to LDL and offer protection against LDL oxidation. We speculate that the difference in response was simply due to person-to-person variation in response to the red wine intervention, as individuals may react differently to supplementation as has been suggested by Howard et al. (2002). Furthermore, the four subjects who did not show an increase in the lag phase did not respond differently in their plasma phenolic concentrations, TBARS or the maximum concentration and the rate of conjugated dienes, leading us to the conclusion that compliance to the intervention was met.

Although there was a trend towards a reduction in the plasma concentration of homocysteine in the red wine group, the results were not statistically significant (Table 3). Elevated circulating homocysteine level is associated with an increased risk of CVD (Refsum et al. 1998) and is affected by diet, mainly due to inadequate intakes of folate and vitamin B\(_12\). There is evidence that a light to moderate consumption of alcohol is associated with lower fasting plasma concentrations of homocysteine; this has previously been reported for beer (van der Gaag et al. 2002) and red wine (Dixon et al. 2002). Although beer contains folate and vitamin B\(_12\), red wine contains negligible amounts of vitamin B\(_12\) and it is unlikely that these micronutrients alone can explain the beneficial effect.

Glucuronides of \((+)-\text{catechin}\) and \((-)-\text{epicatechin}\) and their methylated analogues were identified in plasma from the red wine group post-intervention (Table 4). However, the amounts present could not be quantified and are clearly not sufficient to make a significant contribution to the increased levels of phenolics detected in plasma after red wine consumption (Table 2). The presence of the flavan-3-ol metabolites is, however, in line with the findings of a previous study in which, following consumption of a single serving of 120 ml red wine by human volunteers, \((+)-\text{catechin}\) was detected in plasma after treatment with \(\beta\)-glucuronidase and arylsulphatase (Bell et al. 2000).

Two previous studies (Fuhrman et al. 1996; Nigdikar et al. 1998) have shown a reduction in LDL oxidation using similar doses of red wine (375 ml/d and 400 ml/d, respectively) and intervention periods (2 weeks) as the current study. However, there are a number of possible reasons to explain this apparent discrepancy. The phenolic composition of the wine used in wine trials is important with regard to its effect on LDL oxidation (Howard et al. 2002). In the present study, a Young Vatted Bulgarian Cabernet Sauvignon was used and the intake of phenolic compounds from the 375 ml serving was 165 mg/d, with the majority of the phenolics derived from anthocyanins, gallic acid and total flavan-3-ols (Table 1). The overall levels of phenolics in the wines used in the studies of Nigdikar et al. (1998) and Fuhrman et al. (1996) were somewhat higher than in the present study; for example, the amount of red wine phenolics ingested in the study of Nigdikar et al. (1998) was 248 mg/d in a 375 ml serving. This difference in dose may explain why we observed no statistically significant effect on LDL oxidation.

A further consideration is that in the studies of Nigdikar et al. (1998) and Fuhrman et al. (1996) the LDL oxidation assays were carried out on fresh plasma samples. In our investigation EDTA-treated plasma was stored at \(-80^\circ\text{C}\) for several weeks prior to being assayed. Our experience (Higgins et al. 2001), along with that of Esterbauer et al.
Red wine, antioxidant status and oxidative stress

(1991) and Kleinveld et al. (1992), is that this does not adversely affect the reliability of the LDL oxidation assay. Another difference between the present investigation and the studies of Nigdikar et al. (1998) and Fuhrman et al. (1996) is that in both these studies the volunteers were male, while both male and female volunteers participated in the present study. This could have increased the interindividual variability in the response to the red wine intervention, making it more difficult to see a statistically significant difference in the lag phase between the intervention and control groups.

Although the red wine used in the present study contained a substantial amount of anthocyanins, particularly malvidin-3-glucoside (Table 1), no anthocyanins were detected in plasma despite a thorough search using HPLC with tandem MS. This is in keeping with the findings of other human studies where reported urinary recoveries of anthocyanins after consumption of red wine, or anthocyanin-rich produce, typically range from 0·05 to 0·11% of intake (Frank et al. 2003; McGhie et al. 2003). Similarly, very low plasma anthocyanin concentrations have been reported in man (Cao & Prior, 1999) and frequently the levels are below the limits of detection (Wu et al. 2002; Felgines et al. 2003). It is unclear at this juncture whether anthocyanins enter the circulatory system in trace amounts or whether they are absorbed in more substantial quantities and rapidly removed from the bloodstream.

Likewise, although the red wine contained a high level of gallic acid, despite a thorough search no gallic acid or metabolites of gallic acid were detected in the plasma of volunteers who consumed red wine.

In summary, a moderate consumption, over a 2-week period, of a red wine rich in gallic acid, flavan-3-ols and anthocyanins significantly increased the concentration of total phenolics in the plasma of human volunteers. This small increase may be due to the trace levels of glucoronic acid and methylated metabolites of flavan-3-ol monomers that were detected in plasma after red wine consumption. There were significant reductions in conjugated dienes and TBARS and a significant and modest increase in HDL cholesterol in the group supplemented with red wine. The findings from this study support the protective effects of red wine reported from previous epidemiological studies and current medical opinion that moderate daily intake of red wine may reduce the risk of developing CHD.

Acknowledgements

We thank all volunteers who participated in the study and the Department of Pathological Biochemistry, University of Glasgow, UK for use of their facilities. G.G.D. and S.J.D. are grateful to SEERAD for financial support. We thank Dr Pierre-Louis Teissedre (University of Montpellier, France) for supplying standards of procyanidin dimers. C.T. was supported by a BBiSRC CASE postgraduate studentship with Safeway Stores plc.

References


